Arellano-Ballestero, Helena;
Sabry, May;
Lowdell, Mark W;
(2023)
A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome.
Cells
, 12
(4)
, Article 633. 10.3390/cells12040633.
Preview |
PDF
cells-12-00633.pdf - Published Version Download (942kB) | Preview |
Abstract
Myelodysplastic syndrome (MDS) treatment remains a big challenge due to the heterogeneous nature of the disease and its ability to progress to acute myeloid leukemia (AML). The only curative option is allogeneic hematopoietic stem cell transplantation (HSCT), but most patients are unfit for this procedure and are left with only palliative treatment options, causing a big unmet need in the context of this disease. Natural killer (NK) cells are attractive candidates for MDS immunotherapy due to their ability to target myeloid leukemic cells without prior sensitization, and in recent years we have seen an arising number of clinical trials in AML and, recently, MDS. NK cells are reported to be highly dysfunctional in MDS patients, which can be overcome by adoptive NK cell immunotherapy or activation of endogenous NK cells. Here, we review the role of NK cells in MDS, the contribution of the tumor microenvironment (TME) to NK cell impairment, and the most recent data from NK cell-based clinical trials in MDS.
| Type: | Article |
|---|---|
| Title: | A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome |
| Location: | Switzerland |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3390/cells12040633 |
| Publisher version: | https://doi.org/10.3390/cells12040633 |
| Language: | English |
| Additional information: | This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third-party material in this article are included in the Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| Keywords: | Acute myeloid leukemia, cancer, immunotherapy, myelodysplastic syndrome, natural killer cells, tumor microenvironment, Humans, Myelodysplastic Syndromes, Killer Cells, Natural, Leukemia, Myeloid, Acute, Immunotherapy, Adoptive, Transplantation, Homologous, Tumor Microenvironment |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10165799 |
Archive Staff Only
 |
View Item |
